Format

Send to

Choose Destination
Neurol Clin. 2009 Nov;27(4):1003-1013. doi: 10.1016/j.ncl.2009.06.001.

Identification of pharmacoresistant epilepsy.

Author information

1
Department of Biology, Northern Illinois University, DeKalb, IL 60115, USA. Electronic address: atberg@niu.edu.

Abstract

There is no single definition of pharmacoresistant (intractable, refractory) epilepsy. Prospective identification of pharmacoresistance is complicated by the variability of its appearance across different types of epilepsy and the variability of seizure control within a given patient over time. Failure of informative trials of two appropriate antiepileptic drugs has been recommended as a threshold that should trigger referral for evaluation at a comprehensive epilepsy center. Maximizing seizure control is imperative for reducing the risks and consequences of epilepsy, including the cognitive and psychiatric comorbidities and even sudden death.

PMID:
19853220
PMCID:
PMC2827183
DOI:
10.1016/j.ncl.2009.06.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center